Stay updated with breaking news from Virtual Webcast Event. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lunresertib + camonsertib combination demonstrated clear signals of anti-tumor activity across multiple tumor types and all selected genotypes Overall response of 33.3% across all tumor types and...
Findings from the ongoing Phase 1 MYTHIC study demonstrated a favorable and distinctive tolerability profile for monotherapy lunresertib Monotherapy antitumor activity observed, including confirmed... | June 7, 2023
Initial TRESR data provide clinical proof of concept and validate Repare Therapeutics' SNIPRx platform for molecular selection of tumors for therapy with RP-3500 ... | October 8, 2021